MedTrace Logo

Effects of Different Doses of Caffeine on Physical and Cognitive Performance in Female Handball Players

NCT07562256 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-05-01

No results posted yet for this study

Summary

This study investigates how different doses of caffeine affect physical and cognitive performance in female handball players. Caffeine is widely used as a performance-enhancing substance, but its effects may vary depending on the type of performance and the dose consumed.

In this randomized, double-blind, placebo-controlled crossover study, participants complete three experimental conditions: placebo, low-dose caffeine (3 mg/kg), and moderate-dose caffeine (6 mg/kg). Each participant receives all conditions in a randomized order, with sufficient time between sessions to avoid carryover effects.

The study evaluates three main performance domains relevant to team sports. Physical performance is assessed using an intermittent running test. Cognitive performance is measured using a reaction time task that evaluates attention and inhibitory control. In addition, a throwing test is used to assess sport-specific motor performance.

The main objective is to determine whether caffeine produces dose-dependent improvements and whether these effects differ across physical, cognitive, and technical performance domains. The findings aim to provide practical insights for athletes and coaches regarding optimal caffeine use in team sport settings.

Conditions

  • Athletic Performance
  • Cognitive Performance
  • Healthy Adult Females

Interventions

DIETARY_SUPPLEMENT

Caffeine 6 mg/kg

Acute ingestion of caffeine at a dose of 6 mg per kilogram of body mass, administered in capsule form 60 minutes prior to testing.

OTHER

Placebo

Ingestion of identical capsules containing polydextrose with no active ingredient, administered 60 minutes prior to testing.

DIETARY_SUPPLEMENT

Caffeine 3 mg/kg

Acute ingestion of caffeine at a dose of 3 mg per kilogram of body mass, administered in capsule form 60 minutes prior to testing.

Sponsors & Collaborators

  • Sinop University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
25 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-25
Primary Completion
2026-03-10
Completion
2026-03-20

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07562256 on ClinicalTrials.gov